SCHEDULE: Sirenia Capital Management Discloses 7.7% Stake in OKYO Pharma
Beneficial Ownership Filing
Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 7.7% of OKYO Pharma Ltd's ordinary shares as of March 31, 2026.
Summary
- Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, indicating beneficial ownership of 4,054,054 ordinary shares of OKYO Pharma Ltd.
- This holding represents approximately 7.7% of the company's outstanding ordinary shares.
- The filing date for this statement is May 15, 2026, with the event requiring the filing occurring on March 31, 2026.
- Sirenia Capital Management LP manages the SILV Fund, Ltd., which holds these shares.
- Alex Silverstein is identified as the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It reports a significant ownership stake but provides no operational or financial performance data for OKYO Pharma Ltd itself.
Positives
- Significant stake of 7.7% held by Sirenia Capital Management LP and Alex Silverstein, indicating investor confidence.
- The filing is made under Rule 13d-1(b), suggesting the reporting persons are acting in the ordinary course of business and not to influence control.
Risks
- The filing does not detail specific risks associated with OKYO Pharma Ltd. itself, but rather reports ownership stakes.
- Potential for future changes in ownership or strategy by Sirenia Capital Management LP could impact OKYO Pharma's stock.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding OKYO Pharma Ltd's future performance. It solely reports on beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds acquiring significant stakes in public companies. This filing indicates Sirenia Capital Management LP's strategic interest in OKYO Pharma Ltd, potentially as part of a broader investment strategy within the pharmaceutical or biotechnology sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an institutional investor like Sirenia Capital Management LP may influence market perception and potentially stock price, depending on the investor's strategy.
- Management of OKYO Pharma Ltd: May need to engage with or consider the interests of a substantial shareholder.
- Potential Investors: This filing provides information about a key stakeholder, which can be a factor in investment decisions.
Next Steps
- Monitor future filings by Sirenia Capital Management LP and Alex Silverstein for any changes in their ownership stake in OKYO Pharma Ltd.
- Observe OKYO Pharma Ltd's corporate actions and disclosures for potential strategic shifts or performance updates that may be influenced by significant shareholders.
Key Dates
| Date | Description |
|---|---|
| 2026-02-09 | Ordinary Shares outstanding reported in Issuer's Prospectus filed pursuant to Rule 424(b)(5). |
| 2026-02-17 | Date of Issuer's Prospectus filing. |
| 2026-03-12 | Date of Issuer's Report of Foreign Private Issuer on Form 6-K, detailing shares issued in an offering and exercise of underwriters' overallotment option. |
| 2026-03-31 | Date of Event Which Requires Filing of this Statement (Schedule 13G). |
| 2026-05-15 | Date of signature for the Schedule 13G filing and the Joint Filing Agreement. |
Keywords
OKYO Pharma Ltd, Schedule 13G, Sirenia Capital Management LP, Alex Silverstein, Beneficial Ownership, Ordinary Shares, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.